Browse Category

CRISPR News 15 September 2025 - 7 December 2025

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics AG (NASDAQ: CRSP) is finishing 2025 in classic high‑beta biotech fashion: big science, big headlines, and big disagreement about where the stock goes next. As of the last U.S. trading session on Friday, 5 December 2025, CRSP changed

7 December 2025

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) reuters.com. (Nasdaq closes on Oct 31 showed ~$63.99 reuters.com.) Over the

2 November 2025

Biotechnology · CRISPR · Investing · NASDAQ:BEAM · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · NYSE:AZN · Premarket Analysis · Stock Market

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing

28 October 2025

Biotechnology · CRISPR · Investment News · NASDAQ:NTLA · Pharma Industry · Stock Market

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening

27 October 2025

Biotechnology · CRISPR · Gene Editing · Pharmaceutical Industry · Stock Market

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Stock Price Rollercoaster in 2025 CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels genengnews.com.

27 October 2025

Biotechnology · CRISPR · Gene Editing · Investment Analysis · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · Stock Market

CRISPR ‘Prime Editing’ Breakthrough Cures Genetic Liver Disease in Mice

Breaking the Genetic “Spell” of a Liver Disease Phenylketonuria (PKU) is a hereditary metabolic liver disorder where a single DNA typo disrupts the PAH enzyme that breaks down phenylalanine, an amino acid nature.com fiercebiotech.com. Without a working PAH enzyme, phenylalanine

15 September 2025

Breakthroughs · CRISPR · Genetics · Health · Medical Research

Go toTop